About Neuronex
Neuronex is a Healthcare company based in Morrisville (United States) founded in 2010, and was acquired by Acorda in February 2012. Nasal spray formulation of diazepam is developed for seizure disorders. Neuronex has raised $1.5 million across 2 funding rounds from investors including Acorda. The company was acqui-hired. Its focus areas include Life Sciences, Neurology, Drugs and Neuromuscular. Its legal entity is Neuronex, Inc. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Neuronex was founded in 2010 in Morrisville, United States, as a development-stage company targeting Central Nervous System diseases. A proprietary nasal spray version of diazepam, licensed from SK Biopharmaceuticals, is being developed as rescue medication for patients with seizure disorders. The company was acquired by Acorda in 2012, shifting its operations under the new ownership.
- Headquarters Morrisville, United States
- Stage Acquired
- SectorsHealthcare
- Website neuronexinc.com
- Social LinkedIn
- Acquired by Acorda (Feb 2012)
- Legal Name Neuronex, Inc.
Funding Insights of Neuronex
Neuronex has successfully raised a total of $1.5M across 2 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $400 thousand completed in May 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.5M
- Total Rounds 2
- Last Round Debt – Conventional — $399,999
- First Round $1.5M
(Oct 2010)
All 2 funding rounds of Neuronex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2011 | $399,999 | Debt – Conventional | – | – | – |
| Oct 2010 | $1.5M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Neuronex
Neuronex has secured backing from 1 investor. Prominent investors backing the company include Acorda.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Engaged in the development and commercialization of therapies that improve neurological function. | 1995 | acorda.com | Ardsley, United States |
Investor details for Neuronex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Neuronex
4 dated milestones of Neuronex across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Neuronex is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Debt – Conventional, of $400K.
- Exit Acquired by Acorda.
Competitors of Neuronex
Neuronex has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Neuronex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Neuronex (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Neuronex
Neuronex was founded in 2010.
Neuronex is headquartered in Morrisville, United States.
Neuronex is a funded company, having raised a total of $1.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $1.5M, raised on Oct 2010.
Neuronex was founded in 2010 in Morrisville, United States, as a development-stage company targeting Central Nervous System diseases. A proprietary nasal spray version of diazepam, licensed from SK Biopharmaceuticals, is being developed as rescue medication for patients with seizure disorders. The company was acquired by Acorda in 2012, shifting its operations under the new ownership.
Neuronex's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.
Neuronex has 1 investor. Key investors include Acorda.
Neuronex operates through Neuronex, Inc..
Yes. Neuronex was acquired by Acorda in February 2012.